The business of developing antibacterials

被引：45

作者：

Fox, Jeffrey L.

机构：

[1] freelance writer based in Washington,

[2] D.C.,undefined

来源：

NATURE BIOTECHNOLOGY | 2006年 / 24卷 / 12期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1038/nbt1206-1521

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Although some dazzling technical approaches have fallen short, dozens of small companies and a few major pharmas seek new products for this medically crucial, modest-growth market. © 2006 Nature Publishing Group.

引用

页码：1521 / 1528

页数：8

共 2 条

[1] The big and small of drug discovery - Biotech versus pharma: advantages and drawbacks in drug development [J].

Moore, A .

EMBO REPORTS, 2003, 4 (02) :114-117

[2] Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus [J].

Mygind, PH ;

Fischer, RL ;

Schnorr, KM ;

Hansen, MT ;

Sönksen, CP ;

Ludvigsen, S ;

Raventós, D ;

Buskov, S ;

Christensen, B ;

De Maria, L ;

Taboureau, O ;

Yaver, D ;

Elvig-Jorgensen, SG ;

Sorensen, MV ;

Christensen, BE ;

Kjærulff, S ;

Frimodt-Moller, N ;

Lehrer, RI ;

Zasloff, M ;

Kristensen, HH .

NATURE, 2005, 437 (7061) :975-980

← 1 →